Danaher Corporation $DHR Stock Holdings Boosted by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR boosted its stake in Danaher Corporation (NYSE:DHR) by 7.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 68,832 shares of the conglomerate’s stock after acquiring an additional 4,540 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Danaher were worth $15,250,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Marquette Asset Management LLC grew its stake in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after buying an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC acquired a new position in shares of Danaher during the second quarter worth $25,000. Main Street Group LTD acquired a new position in shares of Danaher during the first quarter worth $25,000. Field & Main Bank acquired a new position in shares of Danaher during the second quarter worth $29,000. Finally, Evolution Wealth Management Inc. lifted its stake in shares of Danaher by 208.0% in the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 104 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research reports. Barclays boosted their price objective on Danaher from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Wells Fargo & Company dropped their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Finally, TD Cowen boosted their price target on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $242.91.

Danaher Stock Performance

Shares of NYSE DHR opened at $232.00 on Wednesday. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a 50 day moving average price of $217.41 and a two-hundred day moving average price of $201.82.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.89 EPS. On average, equities analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.